Literature DB >> 1709117

A homologue of dystrophin is expressed at the neuromuscular junctions of normal individuals and DMD patients, and of normal and mdx mice. Immunological evidence.

F Pons1, N Augier, J O Léger, A Robert, F M Tomé, M Fardeau, T Voit, L V Nicholson, D Mornet, J J Léger.   

Abstract

Polyclonal and monoclonal antibodies, which recognize different regions and epitopes of the dystrophin molecule, bind to a protein of Mr 400,000 which is present in extracts of mdx muscle from regions which contain neuromuscular junctions (NMJ) and is absent from those which do not. This NMJ-associated homologue of dystrophin has at least 2 epitopes which are different to usual Xp21 form of dystrophin expressed along the sarcolemma of muscle fibres in normal muscles. This protein is also expressed at the NMJ of a DMD patient who lacks the first 52 exons of the Xp21 dystrophin gene and it must therefore be translated from a different gene transcript.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709117     DOI: 10.1016/0014-5793(91)80468-i

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Report of ENMC workshop on the limb-girdle muscular dystrophies.

Authors:  A Clarke
Journal:  J Med Genet       Date:  1992-10       Impact factor: 6.318

2.  The fate of dystrophin during the degeneration and regeneration of the soleus muscle of the rat.

Authors:  R Vater; M J Cullen; L V Nicholson; J B Harris
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

Authors:  Annamaria De Luca; Beatrice Nico; Antonella Liantonio; Maria Paola Didonna; Bodvael Fraysse; Sabata Pierno; Rosa Burdi; Domenica Mangieri; Jean-François Rolland; Claudia Camerino; Alberta Zallone; Paolo Confalonieri; Francesca Andreetta; Elisa Arnoldi; Isabelle Courdier-Fruh; Josef P Magyar; Antonio Frigeri; Michela Pisoni; Maria Svelto; Diana Conte Camerino
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

4.  Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle.

Authors:  D J Law; J G Tidball
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

5.  Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

6.  Dystrophin and dystrophin-related protein in the central nervous system of normal controls and Duchenne muscular dystrophy.

Authors:  M Uchino; H Teramoto; H Naoe; T Miike; K Yoshioka; M Ando
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

7.  Xp21 dystrophin and 6q dystrophin-related protein. Comparative immunolocalization using multiple antibodies.

Authors:  T Voit; K Haas; J O Léger; F Pons; J J Léger
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

8.  Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame.

Authors:  L V Nicholson; K M Bushby; M A Johnson; J T den Dunnen; I B Ginjaar; G J van Ommen
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

9.  Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines.

Authors:  T M Nguyen; J M Ellis; D R Love; K E Davies; K C Gatter; G Dickson; G E Morris
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

10.  Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin.

Authors:  Glen B Banks; Ariana C Combs; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2008-09-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.